Accumulation of DC in lamina propria induced by FMS-like tyrosine kinase 3 ligand aggravates the intestinal inflammatory response during endotoxemia.
It is known that the loss of DC plays an important role for immune suppression during endotoxemia or sepsis. To verify our hypothesis that pre-enrichment of the lamina propria (LP) DC pool may improve protective immunity to bacterial translocation and outcome in endotoxemic mice, we pre-treated mice with Flt3L or normal saline, and then challenged them with or without LPS. Twelve hours later the population size and maturity of DC in the LP and circulation were analyzed by flow cytometry. Bacterial translocation to distant organs, inflammatory responses in the intestine and the survival rate of mice were evaluated. We observed that pretreatment of Flt3L significantly expanded DC in the LP and blood, but did not alter their maturation. However, exacerbation of DC growth induced by Flt3L-pretreatment aggravated intestinal inflammation and increased the mortality of endotoxemic mice rather than enhancing their resistance to bacterial translocation.
Research Institute of General Surgery, Clinical School of Nanjing, Second Military Medical University, Jinling Hospital, Nanjing 210002, Jiangsu Province, China.
Xiao-song
XS
Xiang
Yun-zhao
YZ
Zhao
Ning
N
Li
Qiu-rong
QR
Li
Jie-shou
JS
Li
D000818:Animals; D018988:Bacterial Translocation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured; D018925:Chemokines / Q000378:metabolism; D002633:Chemotaxis / Q000187:drug effects; D003713:Dendritic Cells / Q000187:drug effects* / Q000276:immunology / Q000382:microbiology; D004195:Disease Models, Animal; D019446:Endotoxemia / Q000139:chemically induced / Q000276:immunology* / Q000473:pathology; D004926:Escherichia coli / Q000378:metabolism / Q000472:pathogenicity; D005260:Female; D005434:Flow Cytometry; D049452:Green Fluorescent Proteins / Q000096:biosynthesis / Q000235:genetics; D007079:Ileitis / Q000276:immunology* / Q000382:microbiology / Q000473:pathology; D007082:Ileum / Q000187:drug effects* / Q000276:immunology / Q000382:microbiology / Q000473:pathology; D018928:Immunity, Mucosal / Q000187:drug effects; D007274:Injections, Intraperitoneal; D007413:Intestinal Mucosa / Q000187:drug effects / Q000276:immunology; D008070:Lipopolysaccharides; D008565:Membrane Proteins / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D019707:Receptors, Chemokine / Q000378:metabolism; D011994:Recombinant Proteins / Q000008:administration & dosage; D013997:Time Factors; D014162:Transfection
D018925:Chemokines; D008070:Lipopolysaccharides; D008565:Membrane Proteins; D019707:Receptors, Chemokine; D011994:Recombinant Proteins; C084881:flt3 ligand protein; D049452:Green Fluorescent Proteins